Adam Camiel advises life sciences, healthcare and medical technology companies in intellectual property licensing arrangements, strategic collaborations, clinical research arrangements and other complex commercial transactions including mergers and acquisitions and manufacturing arrangements. With a practice spanning the full spectrum of a life science company’s development journey, Mr. Camiel draws on his previous experience in both legal and commercial leadership positions at global pharmaceutical companies to ensure clients hit their business objectives when negotiating a deal.

Mr. Camiel has advised a wide array of clients in the life sciences industry, ranging from early stage and pre-clinical startups to multinational enterprises, as well as private equity-backed ventures, public companies and non-profit organizations, including research institutions. He has experience counseling companies entering complex commercial transactions throughout all stages of the drug development life cycle and across therapeutic areas and call points, with a particular focus in oncology therapeutics. Prior to joining the firm, Mr. Camiel held the positions of both chief of staff and director of corporate legal at a leading US oncology company based in Boston, where he both managed the day-to-day commercial business of the company as well as oversaw a broad array of transformative business transactions and legal initiatives. In addition to his experience as a corporate lawyer, Mr. Camiel has held business leadership positions at multiple large pharmaceutical companies in the fields strategic planning, global marketing and product launches, including most recently leading the launch of a standard of care oncology drug.

Given his experience in leadership positions on both the legal and business sides of growing life sciences companies, Mr. Camiel has a particular expertise in structuring strategic alliances, collaborations and joint ventures.